… diagnosis is important, given the emergence of effective therapies which have revolutionised
the management of transthyretin amyloidosis. … of diagnostic techniques and management …

Hereditary transthyretin amyloidosis (hATTR) with polyneuropathy (formerly known as
Familial Amyloid Polyneuropathy) is a rare disease due to mutations in the gene encoding …

… The purpose of this article is to review the contemporary aspects of diagnosis and
management of transthyretin amyloidosis with cardiac involvement, summarizing also the recent …

… Until very recently, diagnosis of transthyretin amyloidosis (ATTR) was very uncommon and
histological confirmation was mandatory, making diagnosis of ATTR a real challenge in daily …

… Thus, it is crucial for clinicians to be aware of this clinical entity for early diagnosis and proper
treatment. In this mini‐review, we focus on recent advances in diagnosis and treatment of …

… technique to screen asymptomatic transthyretin amyloidosis gene mutation carriers for …
treatment. We will additionally focus on recent advances in treatment for transthyretin amyloidosis‐…

… Most common CA types are light chain amyloidosis (AL) caused by monoclonal immunoglobulin
light chains and transthyretin amyloidosis (ATTR) caused by either mutated or wild-type …

Transthyretin amyloid (ATTR) amyloidosis is an adult-onset, rare systemic disorder characterized
by the accumulation of misfolded fibrils in the body, including the peripheral nerves, the …

… treatment of transthyretin amyloidosis in adult patients with wild-type or hereditary
cardiomyopathy, but is not yet reimbursed. A reimbursement request has to be approved by the …

… The first siRNA-based drug in history to be recently approved by the US FDA for the
treatment of hereditary transthyretin amyloidosis was patisiran, which directly binds to mRNA, …